Fortress Biotech (STU:CNB1) ROCE %: 297.37% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CNB1 Fortress Biotech Inc STU:CNB1
44 GF Score
Price €1.93
GF Value €0.73
! 7 Warning Signs
View Full Analysis

What is Fortress Biotech ROCE %?

Fortress Biotech STU:CNB1 44 ROCE % is 297.37% as of Mar. 2026. GuruFocus rates STU:CNB1 with a GF Score™ of 44/100 and a GF Value™ of €0.73. The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fortress Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was 297.37%.

Fortress Biotech  (STU:CNB1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fortress Biotech ROCE % Related Terms

Fortress Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech ROCE % Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54.92 -91.55 -111.54 -143.22 -22.86

Fortress Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -98.81 -35.85 38.93 -13.71 297.37
STU:CNB1
44GF Score
Fortress Biotech Inc STU:CNB1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortress Biotech ROCE % Calculation

Fortress Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-21.201/( ( (137.733 - 68.186) + (158.458 - 42.481) )/ 2 )
=-21.201/( (69.547+115.977)/ 2 )
=-21.201/92.762
=-22.86 %

Fortress Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=498.452/( ( (158.458 - 42.481) + (308.696 - 89.435) )/ 2 )
=498.452/( ( 115.977 + 219.261 )/ 2 )
=498.452/167.619
=297.37 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 297.37% mean?
Fortress Biotech (STU:CNB1) has a ROCE % of 297.37% as of Mar. 2026.
Is Fortress Biotech's ROCE % too high?
Fortress Biotech's current ROCE % is 297.37%. Overall, Fortress Biotech has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's ROCE % compare to RLYB and INO?
Fortress Biotech's ROCE % of 297.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Fortress Biotech's current ROCE % is 297.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Fortress Biotech (STU:CNB1) has a current ROCE % of 297.37%. The stock's GF Value™ is €0.73, compared to a current price of €1.93 — trading 164.4% above its estimated fair value. The current ROCE % is 297.37%. Fortress Biotech's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Fortress Biotech (STU:CNB1), the current ROCE % is 297.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortress Biotech (STU:CNB1) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of €1.93 is trading 164.4% above its estimated GF Value™ of €0.73.

Key valuation signals for STU:CNB1:

  • ROCE %: 297.37%
  • GF Value™: €0.73 vs. price of €1.93 (164.4% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score

Get the complete analysis for STU:CNB1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.93
Price
€0.73
GF Value